Phase 2 Melanoma Trial, Recruiting NCT05779423 Sponsor: Massachusetts General Hospital Condition: Melanoma
Back to Melanoma

Phase 2 Melanoma Trial, Recruiting

NCT05779423
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult (over 18) with melanoma that cannot be surgically removed, and your cancer has continued to grow or spread after receiving certain immunotherapy treatments (such as pembrolizumab, nivolumab, or ipilimumab)
  • Your doctor is planning to start you on a combination of two immunotherapy drugs: ipilimumab and nivolumab
  • Your doctor considers you healthy enough to receive this two-drug immunotherapy combination
  • You have at least one tumor that a specialist can treat using a needle-based freezing procedure (called cryoablation), guided by imaging
  • You have at least one other measurable tumor, separate from the one being frozen, that doctors can track on scans
  • You have a life expectancy of more than 3 months
  • You are well enough to carry out basic daily activities (confirm with trial site)
  • Your blood, liver, and kidney test results meet certain minimum levels of function (confirm with trial site for specific values)
  • You have had prior radiation therapy, as long as it was not to the specific tumor being frozen
  • If you have HIV, you are on effective treatment and your virus levels were undetectable within the last 6 months
  • If you have or had hepatitis B, your virus levels are undetectable on treatment
  • If you have or had hepatitis C, you have been successfully treated and cured, or your virus is currently undetectable on treatment
  • You have brain tumors that are not causing any symptoms, and your doctor does not feel you need immediate brain-specific treatment
  • You have had or currently have another type of cancer that is unlikely to interfere with this study
  • You are willing and able to read and sign a consent form

Who may not be able to join:

  • The tumor chosen for the freezing procedure has previously been treated with radiation or another local treatment
  • You are unable to safely pause blood-thinning medications before the freezing procedure, if your doctor requires this
  • You are currently taking part in another clinical trial involving an experimental treatment
  • Your cancer is currently getting worse while you are already receiving the combination of ipilimumab and nivolumab
  • You are still experiencing significant side effects (worse than mild) from a previous cancer treatment
  • You have brain tumors or spinal fluid involvement that is causing symptoms
  • You are currently taking more than 10mg of prednisone (or an equivalent steroid) by mouth daily
  • You have another serious illness or medical condition that is not well controlled
  • You are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Meghan J Mooradian, MD, Massachusetts General Hospital

Phone: 617-724-4000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
23 September 2023
Est. completion
1 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of Clinical Benefit

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov